Last reviewed · How we verify
IMX101 vaccine
IMX101 vaccine is a Biologic drug developed by ImevaX. It is currently in Phase 1 development.
At a glance
| Generic name | IMX101 vaccine |
|---|---|
| Sponsor | ImevaX |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMX101 vaccine CI brief — competitive landscape report
- IMX101 vaccine updates RSS · CI watch RSS
- ImevaX portfolio CI
Frequently asked questions about IMX101 vaccine
What is IMX101 vaccine?
IMX101 vaccine is a Biologic drug developed by ImevaX.
Who makes IMX101 vaccine?
IMX101 vaccine is developed by ImevaX (see full ImevaX pipeline at /company/imevax).
What development phase is IMX101 vaccine in?
IMX101 vaccine is in Phase 1.
Related
- Manufacturer: ImevaX — full pipeline
- Compare: IMX101 vaccine vs similar drugs
- Pricing: IMX101 vaccine cost, discount & access